SEOUL-SEMICONDUCTOR
29.10.2021 09:20:08 CEST | Business Wire | Press release
Seoul Semiconductor Co., Ltd. (KOSDAQ 046890), a leading global innovator of LED products and technology, announced that following Seoul National University in Korea and Basel University in Europe, a research team found that exposure to short-wavelength enriched light with daylight-like spectrum improves key components of learning such as working memory, cognitive processing speed, and testing accuracy.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211029005138/en/
The clinical trial began in 2019, conducted by the Division of Sleep and Circadian Disorders at Brigham and Women’s Hospital, a teaching affiliate of Harvard Medical School, and included college-aged adults. The results from the study clearly showed the effectiveness of improving procedural learning.
Shadab Rahman, PhD MPH, a researcher in the Division of Sleep and Circadian Disorders at Brigham and Women’s Hospital and Assistant Professor of Medicine at Harvard Medical School, led the study along with Leilah Grant, PhD, Melissa St. Hilaire, PhD, Steven Lockley, PhD, and other researchers at the Brigham. Dr. Rahman said, “Even if the color temperature and brightness are the same, light with different spectra may affect non-visual responses to light exposure, including those of circadian rhythms and cognition, differently. In this experiment, we found improvement in working memory, cognitive processing speed, procedural learning, and testing accuracy with young adults under daylight-like light spectrum lighting compared to conventional-LED spectrum lighting. This is an important result that can inform lighting choices for indoor use to enhance students’ learning and memory function.”
The daylight-like spectrum lighting used in the study was provided by Seoul Semiconductor Co., Ltd., makers of SunLike. SunLike is an optical semiconductor technology that reproduces the natural sunlight spectrum curve, that is, the intensity of light for each wavelength of red, orange, yellow, green, blue, and purple. This new concept of LED light source embodies almost the same characteristics of natural light and is optimized for human 24-hour circadian rhythm accordingly.
There has been an increase in research activity on the relationship between light and human bio-function, including a recent scientific study focusing on the effects of light spectrum on sleep quality, visual comfort, well-being and daytime alertness conducted by Prof. Christian Cajochen and his team at the University of Basel in Switzerland, entitled: ‘Effect of Daylight LED on Visual Comfort, Melatonin, Mood, Waking Performance, and Sleep,’ published in the Journal of Lighting and Research Technology on March 24, 2019. In addition, in an experiment at Seoul National University College of Medicine in July 2018, it was demonstrated that vitality and alertness were increased when SunLike LED lighting was used.
“As the saying goes, ‘Mother Nature is great’, the human body has a 24-hour circadian clock that has evolved to set its time by tracking the daily cycle of sunlight. SunLike is a technology that reproduces all wavelengths of visible light as closely as possible to sunlight. We've been working on R&D over the past 30 years to optimize this technology to provide plants, animals and humans access to light that is closest to sunlight to promote healthy circadian rhythms and sleep, which can also help children and students to study effectively and maintain good health”, said Chung-hoon Lee, CEO of Seoul Semiconductor.
Seoul Semiconductor and Toshiba Materials were jointly involved in the development and release of SunLike in 2017, which has needed investment to further expand stable production and sales. As a result of continuous consultations between the two companies over the past two years to improve the speed of decision and operational efficiency for the SunLike business, Seoul Semiconductor has acquired all technologies, patents, trademarks, etc. related to SunLike, the light most similar to sunlight. Key workers from Toshiba Materials also joined Seoul Semiconductor, and they began efforts to expand sales from September.
About Seoul Semiconductor
Seoul Semiconductor is the world’s second-largest global LED manufacturer, a ranking excluding the captive market, and has more than 10,000 patents. Based on a differentiated product portfolio, Seoul offers a wide range of technologies, and mass produces innovative LED products for indoor and outdoor lighting, automotive, IT products, such as mobile phones, computer displays, and other applications, as well as the UV area. The company’s world’s first development and mass production products are becoming the LED industry standard and leading the global market with a package-free LED, WICOP; a high-voltage AC-driven LED, Acrich; an LED with 10X the output of a conventional LED, nPola; a cutting edge ultraviolet clean technology LED, Violeds; an all direction light emitting technology, filament LED; a natural sun spectrum LED, SunLike; and more. For more information, please visit www.seoulsemicon.com/en .
View source version on businesswire.com: https://www.businesswire.com/news/home/20211029005138/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Kiabi Selects Navan to Centralise Global Travel Program11.5.2026 09:00:00 CEST | Press release
Fashion retailer targets high employee adoption and efficiency with AI-powered travel platform Navan (NASDAQ: NAVN), the global AI-powered business travel and expense platform, today announced it has been selected by Kiabi, the French multinational fashion retailer, to consolidate its global travel with one unified platform. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260511547434/en/ Fashion retailer targets high employee adoption and efficiency with AI-powered travel platform To support its workforce of nearly 10,000 “Kiabers,” the retailer required a solution capable of providing an easy-to-use travel platform. Navan was selected due to its intuitive AI-powered interface and ability to integrate with Kiabi’s travel policies directly in-app. “Managing travel was becoming an administrative burden that slowed our teams down,” said Denise Maurice, Indirect Procurement Director at Kiabi. “We wanted to give our ‘Kiabers’ the
Owl Labs partners with Westcoast to expand access to seamless hybrid meeting experiences in the UK and Ireland11.5.2026 09:00:00 CEST | Press release
Partnership aims to reduce the ‘meeting tax’ by expanding access to Owl Labs products through Westcoast’s extensive distribution network Owl Labs, a global leader in AI-powered, 360-degree video conferencing solutions, today announced a new UK and Ireland distribution partnership with Westcoast Limited, one of the country’s largest and most trusted IT distributors. The agreement will see Westcoast distribute the full range of Owl Labs’ award-winning Meeting Owl and Owl Bar products across the UK and Ireland, providing greater choice, availability, and dedicated support for resellers and end customers navigating the demands of hybrid work. The partnership aims to address the technical setup challenges that plague meetings across the UK. Owl Labs’ recent State of Hybrid Work report found that nearly 8 in 10 workers (79%) lose time in meetings due to technical difficulties such as connecting to a meeting or setting up a camera. By making Owl Labs’ solutions simpler to source, deploy and s
Fujirebio Announces CE Marking of the Fully Automated Lumipulse® G pTau 217 Plasma Assay11.5.2026 09:00:00 CEST | Press release
H.U. Group Holdings Inc. and its wholly owned subsidiary Fujirebio today announced that Fujirebio Europe N.V. has obtained a CE certificate of the Lumipulse G pTau 217 Plasma assay under the Regulation (EU) 2017/746 on in vitro diagnostic medical devices (IVDR). This CLEIA (chemiluminescent enzyme immunoassay) test allows for the quantitative measurement of Tau phosphorylated at threonine 217 (pTau 217) in human plasma (K2EDTA). “With Lumipulse G NfL Blood and Lumipulse G pTau 217 Plasma now CE‑marked on our LUMIPULSE G platform, we are advancing a new era of neurology diagnostics—one where blood‑based biomarkers enable earlier, broader, and more accessible insights into Alzheimer’s disease and neurodegeneration.” said Christiaan De Wilde, CEO at Fujirebio Europe N.V. “By delivering fully automated and scalable solutions, we are helping clinicians move decisively toward more timely and informed decision‑making. This milestone underscores our long‑term vision to reimagine the diagnostic
Mevion Introduces the First Proton Therapy System Designed for a LINAC Vault at ESTRO 202611.5.2026 08:00:00 CEST | Press release
The MEVION S250-FIT™ creates a new pathway for European cancer centers to integrate proton therapy into existing radiotherapy programs Proton therapy is entering the LINAC vault. At ESTRO 2026, Mevion Medical Systems will introduce the MEVION S250-FIT Proton Therapy System to the European radiation oncology community, the first proton therapy system designed for installation in a standard radiation therapy vault. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260507172087/en/ The MEVION S250-FIT™ Proton Therapy System Now both U.S. FDA-cleared and CE-marked under Regulation (EU) 2017/745, the S250-FIT creates a new pathway for cancer centers to bring proton therapy into existing LINAC-based treatment environments, aligning advanced proton capability with the infrastructure, workflows, and capital planning of modern radiation oncology. Stanford Medicine: First S250-FIT Installation On April 7, 2026, Stanford Medicine unveiled
Vedanta FY26 Profit Soars by 22% to $2.8 bn; Enters Demerger Phase11.5.2026 02:30:00 CEST | Press release
India-based Vedanta Limited (BSE: 500295 & NSE: VEDL), a global leader in metals, oil & gas, critical minerals, power and technology, announced its results for the fourth quarter and full year ended 31 March 2026. It has delivered its best-ever financial performance, driven by structurally strong businesses and disciplined execution. For the full year, Vedanta’s Profit stood at an all-time high of $2.8 bn, reflecting a 22% YoY increase and a profit of $1 bn in Q4 FY26, up nearly 90% YoY. Vedanta reported its highest-ever annual revenue of about $20 bn, up 15% YoY, with Q4 revenue at $5.6 bn, an increase of nearly 30% YoY. The Company maintained strong cost leadership, contributing to record EBITDA of $6.3 bn for FY26, up by about 30% YoY, with margins expanding to around 40%. Q4 EBITDA stood at $2.0 bn, up by nearly 60% YoY, with a margin of approximately 44%. The balance sheet strengthened further, with Net Debt/EBITDA improving to 0.95x, supported by strong cash generation. Underscor
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
